Edward Belk Perry Jr

• Ashley Schnakenberg Martin
• Bao-Zhu Yang
• Brian Pittman
• Carolyn M. Mazure
• Christopher Gottschalk
• Christopher van Dyck
• Deepak Cyril Dsouza
• Elizabeth Ralevski
• Gilles Tamagnan
• Irina Esterlis
• Ismene Petrakis
• John Krystal
• Joseph Lucien Goulet
• Kelly Cosgrove
• Louis Trevisan
• Marina Picciotto
• Rajiv Radhakrishnan
• Robert Makuch
• Sherry McKee

Psycho-Oncology

• Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous SystemLiu Y, Fitzgerald B, Perry E, Pathak A, Chao HH. Prolonged Response to Pembrolizumab in Spindle Cell Squamous Cell Carcinoma Metastatic to the Central Nervous System. Journal Of Investigative Medicine High Impact Case Reports 2019, 7: 2324709619850216. PMID: 31132886, PMCID: PMC6540500, DOI: 10.1177/2324709619850216.
• Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in HumansMathalon DH, Ahn KH, Perry EB, Cho HS, Roach BJ, Blais RK, Bhakta S, Ranganathan M, Ford JM, D’Souza D. Effects of Nicotine on the Neurophysiological and Behavioral Effects of Ketamine in Humans. Frontiers In Psychiatry 2014, 5: 3. PMID: 24478731, PMCID: PMC3900858, DOI: 10.3389/fpsyt.2014.00003.
• Primary cutaneous anaplastic large-cell lymphoma.Perry E, Karajgikar J, Tabbara IA. Primary cutaneous anaplastic large-cell lymphoma. American Journal Of Clinical Oncology 2013, 36: 526-9. PMID: 21552098, DOI: 10.1097/COC.0b013e3182185aa2.
• Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot StudyD'Souza DC, Radhakrishnan R, Perry E, Bhakta S, Singh NM, Yadav R, Abi-Saab D, Pittman B, Chaturvedi SK, Sharma MP, Bell M, Andrade C. Feasibility, Safety, and Efficacy of the Combination of D-Serine and Computerized Cognitive Retraining in Schizophrenia: An International Collaborative Pilot Study. Neuropsychopharmacology 2012, 38: 492-503. PMID: 23093223, PMCID: PMC3547200, DOI: 10.1038/npp.2012.208.
• Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humansRanganathan M, Carbuto M, Braley G, Elander J, Perry E, Pittman B, Radhakrishnan R, Sewell RA, D'Souza DC. Naltrexone does not attenuate the effects of intravenous Δ9-tetrahydrocannabinol in healthy humans. The International Journal Of Neuropsychopharmacology 2012, 15: 1251-1264. PMID: 22243563, DOI: 10.1017/s1461145711001830.
• Preliminary Findings on the Interactive Effects of IV Ethanol and IV Nicotine on Human Behavior and Cognition: A Laboratory StudyRalevski E, Perry EB, D’Souza D, Bufis V, Elander J, Limoncelli D, Vendetti M, Dean E, Cooper TB, McKee S, Petrakis I. Preliminary Findings on the Interactive Effects of IV Ethanol and IV Nicotine on Human Behavior and Cognition: A Laboratory Study. Nicotine & Tobacco Research 2011, 14: 596-606. PMID: 22180582, PMCID: PMC6281082, DOI: 10.1093/ntr/ntr258.
• The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case historiesCarbuto M, Sewell RA, Williams A, Forselius-Bielen K, Braley G, Elander J, Pittman B, Schnakenberg A, Bhakta S, Perry E, Ranganathan M, D’Souza D, The Yale THC Study Group. The safety of studies with intravenous Δ9-tetrahydrocannabinol in humans, with case histories. Psychopharmacology 2011, 219: 885-896. PMID: 21845389, DOI: 10.1007/s00213-011-2417-y.
• Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhalerEsterlis I, Mitsis EM, Batis JC, Bois F, Picciotto MR, Stiklus SM, Kloczynski T, Perry E, Seibyl JP, McKee S, Staley JK, Cosgrove KP. Brain β2*-nicotinic acetylcholine receptor occupancy after use of a nicotine inhaler. The International Journal Of Neuropsychopharmacology 2010, 14: 389-398. PMID: 21029513, PMCID: PMC3510008, DOI: 10.1017/s1461145710001227.
• Clinical significance of neurological soft signs in schizophrenia: Factor analysis of the Neurological Evaluation ScaleSewell RA, Perry EB, Karper LP, Bell MD, Lysaker P, Goulet JL, Brenner L, Erdos J, d'Souza DC, Seibyl JP, Krystal JH. Clinical significance of neurological soft signs in schizophrenia: Factor analysis of the Neurological Evaluation Scale. Schizophrenia Research 2010, 124: 1-12. PMID: 20855185, DOI: 10.1016/j.schres.2010.08.036.
• SPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individualsEsterlis I, Cosgrove KP, Petrakis IL, McKee SA, Bois F, Krantzler E, Stiklus SM, Perry EB, Tamagnan GD, Seibyl JP, Krystal JH, Staley JK. SPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals. Drug And Alcohol Dependence 2010, 108: 146-150. PMID: 20074869, PMCID: PMC2871672, DOI: 10.1016/j.drugalcdep.2009.12.006.
• GABAA‐benzodiazepine receptor availability in smokers and nonsmokers: Relationship to subsyndromal anxiety and depressionEsterlis I, Cosgrove KP, Batis JC, Bois F, Kloczynski TA, Stiklus SM, Perry E, Tamagnan GD, Seibyl JP, Makuch R, Krishnan‐Sarin S, O'Malley S, Staley JK. GABAA‐benzodiazepine receptor availability in smokers and nonsmokers: Relationship to subsyndromal anxiety and depression. Synapse 2009, 63: 1089-1099. PMID: 19642218, PMCID: PMC2778224, DOI: 10.1002/syn.20688.
• β2-Nicotinic Acetylcholine Receptor Availability During Acute and Prolonged Abstinence From Tobacco SmokingCosgrove KP, Batis J, Bois F, Maciejewski PK, Esterlis I, Kloczynski T, Stiklus S, Krishnan-Sarin S, O’Malley S, Perry E, Tamagnan G, Seibyl JP, Staley JK. β2-Nicotinic Acetylcholine Receptor Availability During Acute and Prolonged Abstinence From Tobacco Smoking. JAMA Psychiatry 2009, 66: 666-676. PMID: 19487632, PMCID: PMC2796827, DOI: 10.1001/archgenpsychiatry.2009.41.
• The effects of cannabinoids on serum cortisol and prolactin in humansRanganathan M, Braley G, Pittman B, Cooper T, Perry E, Krystal J, D’Souza D. The effects of cannabinoids on serum cortisol and prolactin in humans. Psychopharmacology 2008, 203: 737. PMID: 19083209, PMCID: PMC2863108, DOI: 10.1007/s00213-008-1422-2.
• Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humansD’Souza D, Pittman B, Perry E, Simen A. Preliminary evidence of cannabinoid effects on brain-derived neurotrophic factor (BDNF) levels in humans. Psychopharmacology 2008, 202: 569. PMID: 18807247, PMCID: PMC2791800, DOI: 10.1007/s00213-008-1333-2.
• LABORATORY STUDIES OF DELTA-9-THC IN HUMANS: RELEVANCE TO SCHIZOPHRENIAD'Souza D, Mathalon D, Perry E. LABORATORY STUDIES OF DELTA-9-THC IN HUMANS: RELEVANCE TO SCHIZOPHRENIA. Schizophrenia Research 2008, 102: 1. DOI: 10.1016/s0920-9964(08)70003-3.
• Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humansD’Souza D, Braley G, Blaise R, Vendetti M, Oliver S, Pittman B, Ranganathan M, Bhakta S, Zimolo Z, Cooper T, Perry E. Effects of haloperidol on the behavioral, subjective, cognitive, motor, and neuroendocrine effects of Δ-9-tetrahydrocannabinol in humans. Psychopharmacology 2008, 198: 587-603. PMID: 18228005, PMCID: PMC2878815, DOI: 10.1007/s00213-007-1042-2.
• Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of CannabisD'Souza DC, Ranganathan M, Braley G, Gueorguieva R, Zimolo Z, Cooper T, Perry E, Krystal J. Blunted Psychotomimetic and Amnestic Effects of Δ-9-Tetrahydrocannabinol in Frequent Users of Cannabis. Neuropsychopharmacology 2008, 33: 2505-2516. PMID: 18185500, PMCID: PMC3799954, DOI: 10.1038/sj.npp.1301643.
• [123I]5-IA-85380 SPECT imaging nicotine occupancy of brain β2-nicotinic acetylcholine receptors after smoking low nicotine and nicotine-free cigarettesEsterlis I, Batis J, Cosgrove K, Bois F, McKee S, Kloczynski T, Stiklus S, O'Malley S, Perry E, Tamagnan G, Seibyl J, Staley J. [123I]5-IA-85380 SPECT imaging nicotine occupancy of brain β2-nicotinic acetylcholine receptors after smoking low nicotine and nicotine-free cigarettes. NeuroImage 2008, 41: t182. DOI: 10.1016/j.neuroimage.2008.04.149.
• Regulation of β2-nAChR during acute and prolonged abstinence from tobacco Smoking: A [123I]5-IA-85380 SPECT imaging studyCosgrove K, Batis J, Bois F, Esterlis I, Stiklus S, Kloczynski T, Maciejewski P, Krishnan-Sarin S, O'Malley S, Perry E, Tamagnan G, Seibyl J, Staley J. Regulation of β2-nAChR during acute and prolonged abstinence from tobacco Smoking: A [123I]5-IA-85380 SPECT imaging study. NeuroImage 2008, 41: t180. DOI: 10.1016/j.neuroimage.2008.04.147.
• Sex differences in nicotinic acetylcholine receptor availability in heavy alcohol drinkersEsterlis I, Bois F, Cosgrove K, Stiklus S, Perry E, Tamagnan G, Seibyl J, Krystal J, Staley J. Sex differences in nicotinic acetylcholine receptor availability in heavy alcohol drinkers. NeuroImage 2008, 41: t183. DOI: 10.1016/j.neuroimage.2008.04.150.
• Single nucleotide polymorphisms of ANKK1 and CHRNA4: Influence on nicotinic acetylcholine receptor availability in nonsmokers measured using [123I]5-IA-85380 SPECTBatis J, Yang B, Cosgrove K, Bois F, Esterlis I, Stiklus S, Kloczynski T, Perry E, Seibyl J, Tamagnan G, Van Dyck C, Gelernter J, Staley J. Single nucleotide polymorphisms of ANKK1 and CHRNA4: Influence on nicotinic acetylcholine receptor availability in nonsmokers measured using [123I]5-IA-85380 SPECT. NeuroImage 2008, 41: t174. DOI: 10.1016/j.neuroimage.2008.04.141.
• The ketamine paradigm in humans: relevance to psychotic disorders.Cho HS, Perry E, Gunduz-Bruce H, D’Souza DC (2008). In: Glutamate in Neuropsychiatric Disorders (Eds: Heresco-Levy U and Javitt DC) pp 1-31. Research Signpost, Kerala, India.
• Absence of Significant Interactive Effects of High‐Dose d‐Cycloserine and Ethanol in Healthy Human Subjects: Preliminary Insights Into Ethanol Actions at the GlycineB Site of NMDA Glutamate ReceptorsTrevisan L, Petrakis IL, Pittman B, Gueorguieva R, D’Souza D, Perry E, Limoncelli D, Krystal JH. Absence of Significant Interactive Effects of High‐Dose d‐Cycloserine and Ethanol in Healthy Human Subjects: Preliminary Insights Into Ethanol Actions at the GlycineB Site of NMDA Glutamate Receptors. Alcohol Clinical And Experimental Research 2007, 32: 36-42. PMID: 18028532, DOI: 10.1111/j.1530-0277.2007.00543.x.
• 123I-5-IA-85380 SPECT Imaging of Nicotinic Acetylcholine Receptor Availability in Nonsmokers: Effects of Sex and Menstrual PhaseCosgrove KP, Mitsis EM, Bois F, Frohlich E, Tamagnan GD, Krantzler E, Perry E, Maciejewski PK, Epperson CN, Allen S, O'Malley S, Mazure CM, Seibyl JP, van Dyck CH, Staley JK. 123I-5-IA-85380 SPECT Imaging of Nicotinic Acetylcholine Receptor Availability in Nonsmokers: Effects of Sex and Menstrual Phase. Journal Of Nuclear Medicine 2007, 48: 1633-1640. PMID: 17873128, DOI: 10.2967/jnumed.107.042317.
• Psychiatric safety of ketamine in psychopharmacology researchPerry EB, Cramer JA, Cho HS, Petrakis IL, Karper LP, Genovese A, O’Donnell E, Krystal JH, D’Souza D. Psychiatric safety of ketamine in psychopharmacology research. Psychopharmacology 2007, 192: 253-260. PMID: 17458544, DOI: 10.1007/s00213-007-0706-2.
• Enhanced Sensitivity to the Euphoric Effects of Alcohol in SchizophreniaD'Souza DC, Gil RB, Madonick S, Perry EB, Forselius-Bielen K, Braley G, Donahue L, Tellioglu T, Zimolo Z, Gueorguieva R, Krystal JH. Enhanced Sensitivity to the Euphoric Effects of Alcohol in Schizophrenia. Neuropsychopharmacology 2006, 31: 2767-2775. PMID: 16985503, DOI: 10.1038/sj.npp.1301207.
• Human Tobacco Smokers in Early Abstinence Have Higher Levels of β2* Nicotinic Acetylcholine Receptors than NonsmokersStaley JK, Krishnan-Sarin S, Cosgrove KP, Krantzler E, Frohlich E, Perry E, Dubin JA, Estok K, Brenner E, Baldwin RM, Tamagnan GD, Seibyl JP, Jatlow P, Picciotto MR, London ED, O'Malley S, van Dyck CH. Human Tobacco Smokers in Early Abstinence Have Higher Levels of β2* Nicotinic Acetylcholine Receptors than Nonsmokers. Journal Of Neuroscience 2006, 26: 8707-8714. PMID: 16928859, PMCID: PMC6674379, DOI: 10.1523/jneurosci.0546-06.2006.
• Greater vulnerability to the amnestic effects of ketamine in malesMorgan CJ, Perry EB, Cho HS, Krystal JH, D’Souza D. Greater vulnerability to the amnestic effects of ketamine in males. Psychopharmacology 2006, 187: 405-414. PMID: 16896964, DOI: 10.1007/s00213-006-0409-0.
• Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of AlcoholismKrystal JH, Madonick S, Perry E, Gueorguieva R, Brush L, Wray Y, Belger A, D'Souza DC. Potentiation of Low Dose Ketamine Effects by Naltrexone: Potential Implications for the Pharmacotherapy of Alcoholism. Neuropsychopharmacology 2006, 31: 1793-1800. PMID: 16395307, DOI: 10.1038/sj.npp.1300994.
• Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive FunctionKrystal JH, Perry EB, Gueorguieva R, Belger A, Madonick SH, Abi-Dargham A, Cooper TB, MacDougall L, Abi-Saab W, D’Souza D. Comparative and Interactive Human Psychopharmacologic Effects of Ketamine and Amphetamine: Implications for Glutamatergic and Dopaminergic Model Psychoses and Cognitive Function. JAMA Psychiatry 2005, 62: 985-995. PMID: 16143730, DOI: 10.1001/archpsyc.62.9.985.
• Cortical γ-Aminobutyric Acid Type A–Benzodiazepine Receptors in Recovery From Alcohol Dependence: Relationship to Features of Alcohol Dependence and Cigarette SmokingStaley JK, Gottschalk C, Petrakis IL, Gueorguieva R, O’Malley S, Baldwin R, Jatlow P, Verhoeff NP, Perry E, Weinzimmer D, Frohlich E, Ruff E, van Dyck CH, Seibyl JP, Innis RB, Krystal JH. Cortical γ-Aminobutyric Acid Type A–Benzodiazepine Receptors in Recovery From Alcohol Dependence: Relationship to Features of Alcohol Dependence and Cigarette Smoking. JAMA Psychiatry 2005, 62: 877-888. PMID: 16061765, DOI: 10.1001/archpsyc.62.8.877.
• Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamineCho HS, D’Souza D, Gueorguieva R, Perry EB, Madonick S, Karper LP, Abi-Dargham A, Belger A, Abi-Saab W, Lipschitz D, Bennet A, Seibyl JP, Krystal JH. Absence of behavioral sensitization in healthy human subjects following repeated exposure to ketamine. Psychopharmacology 2005, 179: 136-143. PMID: 15682309, DOI: 10.1007/s00213-004-2066-5.
• Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or DependencePerry E, Gil R, Miles D, Brenner L, Macdougall L, Johnson R, Degen K, Gueorguieva R, Petrakis I, Krystal J, D'Souza D. Mazindol Augmentation of Antipsychotic Treatment for Schizophrenic Patients with Comorbid Cocaine Abuse or Dependence. Journal Of Dual Diagnosis 2005, 1: 37-47. DOI: 10.1300/j374v01n01_04.
• Mazindol augmentation of antipsychotic treatment for schizophrenic patients with comorbid cocaine abuse or dependence: A preliminary double-blind, randomized, placebo-controlled trialPerry EB, Gil R, Miles D, Brenner L, MacDougall L, Johnson R, Degen K, Gueorguieva R, Petrakis IL, Krystal JK, D’Souza DC. Journal of Dual Diagnosis 2005,1:37-47
• Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjectsKrystal JH, Abi-Saab W, Perry E, D’Souza D, Liu N, Gueorguieva R, McDougall L, Hunsberger T, Belger A, Levine L, Breier A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology 2004, 179: 303-309. PMID: 15309376, DOI: 10.1007/s00213-004-1982-8.
• The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for PsychosisD'Souza DC, Perry E, MacDougall L, Ammerman Y, Cooper T, Wu YT, Braley G, Gueorguieva R, Krystal JH. The Psychotomimetic Effects of Intravenous Delta-9-Tetrahydrocannabinol in Healthy Individuals: Implications for Psychosis. Neuropsychopharmacology 2004, 29: 1558-1572. PMID: 15173844, DOI: 10.1038/sj.npp.1300496.
• Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophreniaD'souza D, Cho H, Perry E, Krystal J. Cannabinoid ‘model’ psychosis, dopamine–cannabinoid interactions and implications for schizophrenia. 2004, 142-165. DOI: 10.1017/cbo9780511543630.012.
• Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial.Perry EB, Berman RM, Sanacora G, Anand A, Lynch-Colonese K, Charney DS. Pindolol augmentation in depressed patients resistant to selective serotonin reuptake inhibitors: a double-blind, randomized, controlled trial. The Journal Of Clinical Psychiatry 2004, 65: 238-43. PMID: 15003079, DOI: 10.4088/jcp.v65n0215.
• Cannabinoid “model” psychosis, dopamine-cannabinoid interactions and implications for schizophrenia.D’Souza DC, Cho H, Perry E, Krystal JH (2004). In: Marijuana and Madness: Psychiatry and Neurobiology (Eds: Murray R and Castle D) pp 142-165. Cambridge University Press, New York.
• S.01.03 Therapeutic implications of the NMDA receptor antagonist model psychosisKrystal J, D'Souza D, Mathalon D, Belger A, Perry E. S.01.03 Therapeutic implications of the NMDA receptor antagonist model psychosis. European Neuropsychopharmacology 2003, 13: s96. DOI: 10.1016/s0924-977x(03)91600-2.
• NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication developmentKrystal JH, D'Souza DC, Mathalon D, Perry E, Belger A, Hoffman R. NMDA receptor antagonist effects, cortical glutamatergic function, and schizophrenia: toward a paradigm shift in medication development. Psychopharmacology 2003, 169: 215-233. PMID: 12955285, DOI: 10.1007/s00213-003-1582-z.
• Cannabinoids and psychosis: Pharmacological studies with IV delta-9-THC in humansD'Souza D, Perry E, Riccardi P, Abi-Saab W, Krystal J. Cannabinoids and psychosis: Pharmacological studies with IV delta-9-THC in humans. Schizophrenia Research 2003, 60: 310. DOI: 10.1016/s0920-9964(03)80247-5.
• Clozapine-induced weight gain predicts improvement in psychopathology.Meltzer HY, Perry E, Jayathilake K. Clozapine-induced weight gain predicts improvement in psychopathology. Schizophrenia Research 2003, 59: 19-27. PMID: 12413638, DOI: 10.1016/s0920-9964(01)00326-7.